Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | FNTA | P49354 | 3/20 | 0.33 |
| ▸ | PGGT1B | P53609 | 3/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | FNTB | P49356 | 2/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | WEE1 | P30291 | 1/20 | 0.32 |
| ▸ | TGM2 | P21980 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20037476 | 0.89 | HSP90AA1 (0.35) | OPRL1HRH3FNTAPGGT1BKCNH2 | |
| SCHEMBL20038395 | 0.85 | TLR8 (0.38) | OPRL1HRH3KCNH2DRD3ALDH1A1 | |
| SCHEMBL20038387 | 0.85 | MDM2 (0.36) | HTTSMN1; SMN2HRH3KCNH2HRH1 | |
| SCHEMBL20038349 | 0.85 | KCNH2 (0.47) | HTTSMN1; SMN2OPRL1HRH3S1PR1 | |
| SCHEMBL20255265 | 0.83 | DRD3 (0.36) | OPRL1HRH3KCNH2DRD3WEE1 | |
| SCHEMBL20038197 | 0.80 | AR (0.36) | HRH3FNTAPGGT1BKCNH2FNTB | |
| SCHEMBL20255524 | 0.80 | PIK3CD (0.35) | HRH3KCNH2DRD3 | |
| SCHEMBL20255472 | 0.80 | DRD3 (0.35) | HRH3FNTAPGGT1BKCNH2FNTB | |
| SCHEMBL20038056 | 0.80 | PIK3CD (0.46) | FNTAPGGT1BKCNH2FNTBDRD3 | |
| SCHEMBL23291481 | 0.78 | KMT2A (0.47) | HTTSMN1; SMN2HRH3FNTAPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| EP-3305785-A1 | PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Teijin Pharma Limited (JP) | 2018-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | HTT 3754/4885SMN1; SMN2 1690/4885OPRL1 4655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.